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© 2013 The Japan Society of Histochemistry andLeptin is a hormone mainly produced by white adipose cells, and regulates body fat and
food intake by acting on hypothalamus. Leptin receptor is expressed not only in the
hypothalamus but in a variety of peripheral tissues, suggesting that leptin has pleiotropic
functions. In this study, we investigated the effect of leptin on the progression of peritoneal
fibrosis induced by intraperitoneal injection of chlorhexidine gluconate (CG) every other day
for 2 or 3 weeks in mice. This study was conducted in male C57BL/6 mice and leptin-deficient
ob/ob mice. Peritoneal fluid, blood, and peritoneal tissues were collected 15 or 22 days after
CG injection. CG injection increased the level of leptin in serum and peritoneal fluid with
thickening of submesothelial compact zone in wild type mice, but CG-injected ob/ob mice
attenuate peritoneal fibrosis, and markedly reduced the number of myofibroblasts, infiltrating
macrophages, and blood vessels in the thickened submesothelial area. The 2-week leptin
administration induced a more thickened peritoneum in the CG-injected C57BL/6 mice than
in the PBS group. Our results indicate that an upregulation of leptin appears to play a role
in fibrosis and inflammation during peritoneal injury, and reducing leptin may be a
therapeutically potential for peritoneal fibrosis.
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I. Introduction
Peritoneal dialysis (PD) is a beneficial therapy for
end-stage renal disease, but long-term use of PD induces
histopathologic changes in the peritoneum, such as perito-
neal fibrosis with increased submesothelial collagen depo-
sition and loss of mesothelial cells [4, 7, 18, 34]. In
particular, some patients develop encapsulating peritoneal
sclerosis (EPS) associated with high mortality, which is one
of the most serious complications in PD patients [9]. The
mechanism of peritoneal fibrosis in PD patients remains
poorly understood and no effective therapy is available at
present.
Leptin is mainly produced by white adipose cells [37]
and plays an important role in body weight regulation by
inhibiting food intake via hypothalamic effects and stimu-
lating energy expenditure in skeletal muscle cells [6].
However, the leptin receptor is expressed not only in the
hypothalamus but in a variety of peripheral tissues, suggest-
ing that leptin has pleiotropic functions. To date, the periph-
eral actions of leptin have been reported such as activation
of platelet aggregation, modulation of immune functions,
and acceleration of angiogenesis [14, 19, 23, 27]. These
findings suggest that leptin acts as a pro-inflammatory
cytokine in peripheral tissues. Recent studies have sug-
gested an essential fibrogenic role for leptin in experimental
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liver fibrosis [8, 20, 29]. In addition, previous reports
demonstrated that leptin-deficient (ob/ob) mice, which lack
hypothalamic inhibition of appetite, leading to obesity,
insulin resistance, and type II diabetes [2], are protected
from inflammation and fibrosis in various disease models,
including autoimmune encephalomyelitis [15], liver fibrosis
[21], nephrotoxic nephritis [31], and interstitial fibrosis by
unilateral ureteral obstruction (UUO) [11]. In fact, PD
patients showed high levels of leptin in their serum or
peritoneal dialysate [5, 33]. However, the role of leptin in
peritoneal fibrosis has not been elucidated.
Thus, in the present study, we investigated the effect
of leptin using leptin-deficient (ob/ob) mice in the devel-
opment of peritoneal fibrosis induced by chlorhexidine
gluconate (CG).
II. Material and Methods
Animals
The experiments described in this study were con-
ducted in male C57BL/6 mice weighing 22.6±1.1 g body
weight, and leptin-deficient ob/ob mice (C57BL/6J-Lepob/
Lepob) weighing 37.3±1.3 g body weight (Japan Charles
River Inc., Yokohama, Japan). They were housed in a
light- and temperature-controlled room in Biomedical
Research Center, Center for Frontier Life Sciences,
Nagasaki University. They had free access to laboratory
chow and tap water in standard rodent cages. The experi-
mental protocol was inspected by Animal Care and Use
Committee of Nagasaki University, and approved by the
President of Nagasaki University (approval number:
1004050846-5).
Experimental protocol
Peritoneal fibrosis was induced by intraperitoneal
injection of 0.05% CG in 15% ethanol dissolved in saline,
as described previously with a slight modification [3, 36].
Mice received injections of CG into the peritoneal cavity at
a volume of 10 ml/kg body weight 3 times a week for 3
weeks. Control group of mice received an equal volume of
vehicle intraperitoneally. Mice were divided into four
groups: (i) wild type C57BL/6 mice injected vehicle intra-
peritoneally defined as the WT-control group, (ii) ob/ob
mice injected vehicle intraperitoneally defined as ob/ob-
control group, (iii) wild type C57BL/6 mice injected CG
intraperitoneally defined as the WT-CG group, (iv) ob/ob
mice injected CG intraperitoneally defined as the ob/ob-CG
group. Each group consisted of 5 mice. At days 22 after
the first CG injection, mice were infused with 2 ml of
saline into the abdominal cavity under anesthesia. 30 min-
utes after infusion, peritoneal fluid was collected for the
examination of leptin level. Blood samples were drawn
from all animals by transthoracic cardiac puncture under
anesthesia prior to sacrifice. Then, mice were sacrificed,
and peritoneal tissues were dissected out carefully. To
avoid direct damage to the peritoneum caused by repeated
injections, injections of CG were made at the lower part of
the peritoneum, while the upper portion of the parietal
peritoneum was used for the following examination. Tissues
were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) (pH 7.4). In addition, frozen tissues were
also prepared by mounting in optimal cutting temperature
compound (Miles, Inc., Elkhart, IN, USA) and rapidly
frozen in dry ice and stored at –80°C until use. Fresh frozen
tissues were cut into 4-μm-thick sections using a microtome
and placed onto aminopropyltriethoxysilane-coated slide
glasses.
Leptin administration
Recombinant mouse leptin (498-OB, R&D Systems,
Inc., Minneapolis, MN, USA) was diluted in a vehicle (15
mM HCL and 7.5 mM NaOH) according to the manufac-
turer’s protocol and adjusted to 1.25 mg/ml. The mice
received CG injections into the peritoneal cavity at a
volume of 10 ml/kg of body weight, 3 times a week for 2
weeks (WT-CG group). During the first CG injection, we
implanted an ALZET® osmotic pump (1002, DURECT
Corp., Cupertino, CA, USA) containing recombinant leptin
(0.45 g/kg/day), which was released in a sustained manner
for 2 weeks, in the mice subcutaneously injected with CG.
The WT-CG group was divided into (1) an experimental
group, which comprised mice administered recombinant
leptin and defined as the leptin group (n=3), and (2) a
control group, which comprised mice administered PBS
instead of leptin and defined as the PBS group (n=3). At
day 15 after the first CG injection, the mice were killed and
peritoneal tissues were dissected out carefully, as described
previously.
Histologic and immunohistochemical examination
For morphological examination, 4-μm thick paraffin-
embedded tissues were stained with hematoxylin and eosin
(HE). The immunohistochemical procedure used in the
present study was described previously [1, 3, 25]. The first
antibodies used for immunohistochemistry in this study
are listed in Table 1. We used fresh frozen sections for
CD31 staining, and paraffin-embedded sections for detec-
tion of all the rest of factors. Indirect immunohistochemical
technique was used for collagen III, F4/80, and CD31.
Deparaffinized tissue sections were incubated for 30 min
with a blocking buffer containing 5% normal goat serum,
5% fetal calf serum, 5% bovine serum albumin, and 20%
normal swine serum in PBS. The sections were then
reacted with the primary antibody, and diluted in the
same blocking buffer. After reacting with anti-collagen III
antibody for 1 hr at room temperature, sections were
reacted with horseradish peroxidase (HRP)-conjugated
swine anti-rabbit immunoglobulin antibody (P0399; Dako)
diluted 1/50 for 30 min at room temperature, and a complex
of rabbit anti-HRP antibody and HRP (Z0113; Dako)
diluted 1/100 for 30 min at room temperature. For F4/80
and CD31, sections were reacted with HRP-conjugated
rabbit anti-rat immunoglobulin antibody (Z0147; Dako) and
HRP-conjugated swine anti-rabbit immunoglobulin anti-
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body after reacting with primary antibodies for 1 hr at
room temperature. We used direct immunohistochemical
technique for detection of α-smooth muscle actin (SMA).
After deparaffinization, the sections were incubated for
30 min with a blocking buffer similar to that described
above, and then reacted with anti-α-SMA antibody for 1 hr
at room temperature. For leptin, leptin receptor, trans-
forming growth factor-beta (TGF-β), monocyte chemotactic
protein-1 (MCP-1), vascular endothelial growth factor
(VEGF) staining, deparaffinized tissues were stained with
avidin-biotin complex technique using Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA) after
reacting with first antibody for 1 hr at room temperature.
Reaction products were visualized by treating sections with
H2O2 and 3,3'-diaminobenzidine tetrahydrochloride. Finally,
the sections were counterstained with methyl green and
mounted. For all specimens, negative controls were pre-
pared with irrelevant mouse monoclonal antibody, rat
monoclonal antibody, or the normal rabbit IgG in place of
the primary antibody.
Morphometric analysis
To assess the extent of peritoneal thickening, we used
digitized images and image analysis software (Win ROOF
MITANICORP, Chiba, Japan). The image was transformed
into a matrix of 1280×1024 pixels and viewed at ×200
magnification. We selected a width of 421 μm in the
examined field under the microscope and measured the
area of the submesothelial layer within the selected width
of 421 μm. For each sample, 10 areas were selected and
the average area of the submesothelial compact zone or
collagen III-positive area was determined. In each peri-
toneal sample, the numbers of α-SMA-expressing cells,
TGF-β-expressing cells, F4/80-positive macrophages, MCP-
1-expressing cells, CD31-positive vessels, and VEGF-
expressing cells and were counted in 10 fields at ×400
magnification.
Leptin measurements
Leptin concentration of serum and peritoneal fluid
were measured with a commercially available ELISA kit
(MOB00; R&D systems). Blood samples were drawn
from all animals by transthoracic cardiac puncture under
anesthesia prior to sacrifice. Serum was obtained by centri-
fuging whole blood at 3000 rpm, 4°C, and for 5 min.
Statistical analysis
Data are expressed as mean±standard deviation (SD).
Differences among groups were examined for statistical
significance using repeated measures analysis of variance
(ANOVA) (Bonferroni/Dunn test). A P value less than 0.05
denoted the presence of statistically significant difference.
III. Results
Leptin level of serum and peritoneal fluid
We examined the concentration of leptin in serum and
peritoneal fluid of CG-treated wild-type mice and untreated
one. In both serum and peritoneal fluid, leptin levels were
increased by CG injection (Table 2). Similarly, we con-
firmed the increased expression of leptin in the peritoneum
of CG-injected C57BL/6 mice by immunohistochemical
examination (Fig. 1a and b). In ob/ob mice, leptin-deficient
mice, the leptin was not detected with or without CG
injection (data not shown).
Immunohistochemical analysis for leptin receptor in 
peritoneum
In peritoneum of WT-control group, leptin receptor
was only localized in mesothelial cells (Fig. 2a). In the
ob/ob-control group, a pattern of leptin receptor expression
Table 1. The list of primary antibodies for immunohistochemistry
α-SMA; α-smooth muscle actin, EPOS; enhanced polymer one-step staining, TGF-β; transforming growth factor-beta, MCP-1; monocyte
chemotactic protein-1, VEGF; vascular endothelial growth factor.
Primary Antibodies Host Dilution Company
leptin receptor goat 1:50 GT15012; Neuromics, Northfield, MN, USA
leptin goat 1:100 GT15011; Neuromics, Northfield, MN, USA
collagen III rabbit 1:400 LB-1393; LSL Co., Tokyo, Japan
α-SMA (myofibroblasts) mouse EPOS U7033; Dako, Glostrup, Denmark
TGF-β rabbit 1:200 sc-146; Santa Cruz Biotechnology, Santa Cruz, CA, USA
F4/80 (macrophages) rat 1:100 MCA497; Serotec, Oxford, UK
MCP-1 goat 1:100 sc-1784; Santa Cruz Biotechnology, Santa Cruz, CA, USA
CD31 (endothelial cells) rat 1:50 1625-01: Southern Biotechnology, Birmingham, AL, USA
VEGF rabbit 1:100 sc-507; Santa Cruz Biotechnology, Santa Cruz, CA, USA
Table 2. Leptin concentration of serum and peritoneal fluid in wild
type mice and ob/ob mice
* P<0.01 vs untreated wild type mice.
wild type ob/ob
untreated CG-treated untreated CG-treated
Serum 
(ng/ml)
1.08±0.59 4.74±1.81* 0 0
Peritoneal fluid 
(ng/ml)
0.07±0.04 0.54±0.35* 0 0
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Fig. 1. Immunohistochemistry for leptin. In the WT-control group, leptin expression was not observed in the peritoneum (a). In contrast, an
increase in leptin expression was observed in the CG-injected C57BL/6 mice (b).
Fig. 2. Immunohistochemistry for leptin receptor. Leptin receptor expression was observed in the peritoneal tissues of the WT-control group
(a), CG-treated C57BL/6 mice (c), and CG-injected ob/ob mice (e). The peritoneal tissue sections of the WT-control group (b), CG-treated
C57BL/6 mice (d), and CG-injected ob/ob mice (f) were incubated with normal goat IgG instead of leptin receptor antibody as negative
controls. The black arrowhead shows the leptin receptor-positive mesothelium. Magnification, ×400.
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in the peritoneum was shown similar to that of WT-control
group (data not shown). Meanwhile, the expression of
leptin receptor in peritoneum of CG-injected mice was
increased compared to that in control group and the leptin
receptor in peritoneum of CG-injected wild type mice was
identified at myofibroblasts, macrophages, and mesothelial
cells (Fig. 2c). Moreover, CG-injected ob/ob mice showed
a pattern of leptin receptor expression in the peritoneum
similar to that of CG-injected wild type mice (Fig. 2e). No
staining was found in sections that were reacted with goat
IgG as negative controls (Fig. 2b, d, and f).
Morphologic examination
We next investigated the degree of peritoneal fibrosis
induced by CG in wild-type mice and ob/ob mice. In
WT-control mice and ob/ob-control mice, a monolayer of
mesothelial cells was observed covering the surface without
any thickening of the peritoneum (Fig. 3a and c). CG
injection induced significant thickening of submesothelial
compact zone in WT-CG group (Fig. 3b). Meanwhile, the
area of submesothelial compact zone in ob/ob-CG group
was significantly smaller than that in the WT-CG group
(Fig. 3d).
Fig. 3. HE staining. In the WT-control group, injected with
vehicle, the peritoneum was only slightly thickened (a),
while CG injection induced significant thickening of the
peritoneum in WT-CG group (b). In the ob/ob-control group,
submesothelial area was as same as that in the WT-control
group (c). In the ob/ob-CG group, the progression of perito-
neal fibrosis was significantly suppressed compared with
WT-CG group (d). Bar graph shows the semiquantitative
analysis of area of the submesothelial compact zone (e).
Magnification: ×200; bars indicate the thickness of the sub-
mesothelial compact zone. Data are expressed as mean±SD;
* represents P<0.01 vs WT-control or ob/ob-control group,
** represents P<0.01 vs WT-CG group.
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Expression of collagen III, α-SMA, and TGF-β
The results of immunohistochemical analysis for col-
lagen III, α-SMA and TGF-β at day 21 are shown in Fig. 4.
CG injection significantly increased the accumulation of
collagen III in the submesothelial area (Fig. 4a), while the
positive area of collagen III was significantly reduced in
ob/ob-CG group (Fig. 4b and c).
We examined the expression of α-SMA, a marker
of myofibroblasts, which are major source of collagen-
producing cells. In the WT-CG group, numerous α-SMA-
positive myofibroblasts were identified in the thickened
peritoneal tissues (Fig. 4d). Compared with WT-CG group
(Fig. 4d), the number of α-SMA-expressing cells was
markedly reduced in ob/ob-CG group (Fig. 4e and f). We
also investigated the expression of profibrotic cytokine
TGF-β in the thickened peritoneum. In the WT-CG group,
the large number of TGF-β-expressing cells was presented
in the peritoneum (Fig. 4g). On the contrary, ob/ob-CG
group showed a significant decrease of the number of TGF-
β-positive cells in the peritoneum (Fig. 4h and i).
Expression of F4/80 and MCP-1
To examine the effect of leptin on the macrophage
infiltration in the peritoneum, we performed immuno-
histochemistry for F4/80 as a marker for mouse macro-
phages on peritoneal tissues. In the WT-CG group, a large
number of F4/80-positive macrophages was observed in
the thickened peritoneum (Fig. 5a), while the number of
F4/80-positive macrophages was markedly reduced in the
ob/ob-CG group (Fig. 5b and c). We also investigated the
expression of MCP-1, which exerts an important role on
macrophage infiltration. The number of MCP-1-expressing
cells was increased in the thickened submesothelial com-
pact zone (Fig. 5d). In the ob/ob-CG group (Fig. 5e), the
number of MCP-1-expressing cells was significantly less
than that in WT-CG group (Fig. 5f).
Fig. 4. Immunohistochemistry for collagen III, α-SMA, and TGF-β. In the WT-CG group, collagen III was strongly expressed in the sub-
mesothelial compact zone (a), while the expression of collagen III in ob/ob-control group was less than that in WT-CG group (b). Bar graph
shows the semiquantitative analysis of collagen III-positive area (c). Note the presence of numerous α-SMA-expressing cells in the thickened
submesothelial compact zone of the WT-CG group (d). In the ob/ob-CG group, the number of α-SMA-expressing cells was reduced (e). Bar
graph shows the quantitative analysis of α-SMA-expressing cells (f). A large number of TGF-β-positive cells were observed in the thickened
submesothelial compact zone of the WT-CG group (g). In the ob/ob-CG group, the number of TGF-β-positive cells was decreased (h).
Bar graph shows the quantitative analysis of TGF-β-positive cells (i). Magnification, ×400; bars indicate the thickness of the submesothelial
compact zone. Data are expressed as mean±SD; * represents P<0.01 vs WT-CG group.
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Expression of CD31 and VEGF
We investigated the number of blood vessels using
immunohistochemistry for CD31. The large number of
CD31-positive vessels was identified in the WT-CG group
(Fig. 5g). The number of CD31-expressing vessels was
significantly decreased in the peritoneum of ob/ob-CG
group (Fig. 5h and i) compared to that of WT-CG group.
We also examined the expression of VEGF, a potent
stimulator of angiogenesis, in the submesothelial zone in
our model. The mice in the WT-CG group exhibited a large
number of VEGF-positive cells in the thickened peritoneum
(Fig. 5j). Peritoneal tissues in the ob/ob-CG group con-
Fig. 5. Immunohistochemistry for F4/80, MCP-1, CD31, and VEGF. Numerous F4/80-positive macrophages were present in thickened
peritoneal tissues of the WT-CG group (a). In the ob/ob-CG group, the number of F4/80-positive macrophages was reduced (b). Bar graph
shows the quantitative analysis of F4/80-positive macrophages (c). Note the large number of MCP-1-positive cells in the thickened sub-
mesothelial compact zone of the WT-CG group (d). In the ob/ob-CG group, the number of MCP-1-positive cells in the submesothelial compact
zone was significantly less than that in the WT-CG group (e). Bar graph shows the quantitative analysis of MCP-1-positive cells (f). Note the
presence of numerous CD31-positive vessels in the WT-CG group (g). On the contrary, a few number of CD31-positive vessels in the ob/ob-
control group (h). Bar graph shows the quantitative analysis of CD31-positive vessels (i). In the WT-CG group, the number of VEGF-positive
cells was increased in the thickened submesothelial compact zone (j), while it was markedly decreased in ob/ob-control group compared with
WT-CG group (k). Bar graph shows the quantitative analysis of VEGF-positive cells (l). Magnification, ×400; bars indicate the thickness of the
submesothelial compact zone. Data are expressed as mean±SD; * represents P<0.01 vs WT-CG group.
Nakazawa et al.82
tained a significant smaller number of VEGF-expressing
cells in the submesothelial area than that in the WT-CG
group (Fig. 5k and l).
Effects of leptin administration on peritoneal fibrosis
To confirm the effect of leptin on the progression of
peritoneal fibrosis, we administered recombinant leptin
through an osmotic pump to the CG-injected WT mice. CG
injection significantly increased the accumulation of col-
lagen III in the submesothelial area (Fig. 6a). In particular,
the positive area for collagen III was found to be signifi-
cantly more increased in the leptin group than in the PBS
group (Fig. 6b and c).
IV. Discussion
In the present study, we showed that CG injection
increased the level of leptin in serum and peritoneal fluid
with thickening of submesothelial compact zone in wild
type mice. Similarly, we confirmed the increased expres-
sion of leptin in the peritoneum of CG-injected C57BL/6
mice by immunohistochemical examination. We also dem-
onstrated increased expression of leptin receptors by CG
injection, independent of leptin expression. Moreover, we
demonstrated that leptin-deficient mice, ob/ob mice, atten-
uate peritoneal fibrosis induced by CG in the experimental
mouse model. In addition, CG-injected ob/ob mice revealed
markedly reduced the number of myofibroblasts, infiltrating
macrophages, and blood vessels in the thickened sub-
mesothelial area. Meanwhile, leptin administration induced
a more severe peritoneal fibrosis in the WT-CG group than
in the PBS group.
Although the pathogenesis of peritoneal fibrosis in PD
patients is still unclear, many factors are considered to be
involved in the development of peritoneal fibrosis. In the
present study, we used a mouse experimental model of
peritoneal fibrosis induced by CG. Suga et al. [26] and Ishii
et al. [9] developed experimental models for peritoneal
fibrosis in rats and EPS in mice, respectively, by peritoneal
injection of CG. Whether this model is relevant to the
peritoneal sclerosis and encapsulating peritoneal sclerosis
seen in PD patients remains to be determined. However, it
can be assumed that certain common pathways exist during
the development of peritoneal fibrosis between our model
and the PD patients. In fact, following injection of CG as
a nonspecific chemical to induce peritoneal fibrosis,
many pathologic findings in the peritoneum of PD patients,
including increased expression of collagen III, α-SMA,
macrophages infiltration, were also observed in our model.
These similarities in alterations of the peritoneal mem-
branes between experimental CG models and human PD
patients strongly suggest that the CG model is a reasonable
candidate model for examining the efficacy of various
potential therapeutic reagents for regulating peritoneal
sclerosis.
Adipose tissue is ubiquitously present in peritoneal
tissue and it is known that patients on PD have increased
fat mass due to glucose absorption from the PD fluid.
Recently, peritoneal adipocytes have been suggested to play
an important role in chronic inflammation through the
release of adipokines [24, 32]. Among these adipokines, a
marked increase in leptin concentration from serum and
dialysate of patients undergoing PD has been reported
[33]. In patients with PD, the serum level of leptin is
increased because of decreased excretion from kidney. In
addition, it has been known that there are some specific
factors for patients undergoing PD, such as unphysiological
high glucose PD fluid or peritonitis, which promote local
synthesis of leptin through IL-1β and TNF-α [12, 13]. Since
CG injection causes chemical inflammation and increases
proinflammatory cytokines including IL-1β and TNF-α
[35], we considered that these cytokines stimulate leptin
synthesis in the peritoneal cavity in CG-injected mice.
Moreover, the leptin receptor expression was also up-
regulated in the CG-injected mice, independent of leptin
expression. Matsui et al. previously reported that leptin and
leptin receptor expressions were induced after ischemia/
reperfusion [16]. Although the precise mechanism of these
findings is unknown, leptin and leptin receptor expressions
have been suggested to be regulated by various mediators
Fig. 6. Effects of leptin administration on peritoneal fibrosis. Immunohistochemistry for collagen III in the peritoneal tissues of the mice infused
with PBS (a) or leptin (b) via osmotic pump for 14 days. Compared with the PBS group (a), the leptin-infused mice indicated significant accu-
mulation of collagen III in the submesothelial compact zone (e). The bar graph shows the result of the semiquantitative analysis of the collagen
III-positive area (f). Magnification, ×400. The bars indicate the thickness of the submesothelial compact zone. The data are expressed as
mean±SD; * represents P<0.01 vs PBS group.
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such as inflammatory cytokines and oxidative stress. Given
that the pathophysiological mechanism was reported to be
involved in inflammation or oxidative stress in a CG-
induced peritoneal fibrosis model [10, 35], these factors
might upregulate the expression of not only leptin but also
the leptin receptor in our study.
TGF-β is known to play an essential role on the
progression of fibrosis. Leung et al. also demonstrated
that leptin induces TGF-β synthesis through the functional
leptin receptor expressed by human mesothelial cells [13].
Moreover, Kumpers et al. showed that leptin can serve as
a cofactor of TGF-β activation [11]. Thus, leptin deletion
might lead to a significant decrease of the number of
TGF-β-positive cells and fail to activate TGF-β signaling
in the peritoneum of CG-injected ob/ob mice in our study.
Based on the previous data [17, 22], macrophage infiltration
also may play an important role in the development of
peritoneal fibrosis. Recently, Tanaka et al. demonstrated
that leptin administration in ob/ob mice accelerated renal
macrophage infiltration through the melanocortin system in
unilateral ureteral obstruction model [28]. Therefore, it is
possible that leptin deletion led to suppression of macro-
phage infiltration and prevention of peritoneal fibrosis in
our model. Furthermore, leptin promotes angiogenesis via
upregulation of VEGF [30]. Similarly, we confirmed the
upregulation of VEGF and angiogenesis in CG mice and a
decreased number of VEGF-positive cells and vessels in
CG injected-ob/ob mice. Taken together, these findings
seemed to support that increased leptin contribute to the
progression of fibrosis through various pathways.
In conclusion, we found that in wild-type mice, CG
treatment cause the progression of peritoneal fibrosis
through increase of TGF-β expressing cells, infiltrating
macrophages, and angiogenesis. All of these parameters
were decreased in peritoneal tissues of CG-injected ob/ob
mice. In addition, we also demonstrated that leptin admin-
istration in the CG-injected mice aggravated peritoneal
fibrosis. Thus, an upregulation of leptin appears to play a
role in fibrosis and inflammation during peritoneal injury.
Our results indicate the involvement of leptin in the
progression of peritoneal fibrosis and treatment strategy
for reducing leptin may be a therapeutically potential for
peritoneal fibrosis.
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